Navigation Links
Cardium to Present at Southern California Investor Conference
Date:8/26/2011

SAN DIEGO, Aug. 26, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that Christopher J. Reinhard, Chairman and Chief Executive Officer, is scheduled to present at the Southern California Investor Conference on Monday, August 29, 2011, at 9:30 a.m. (Pacific) at the Island Hotel in Newport Beach, California.  The slide presentation will be available at the Company's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

About CardiumCardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium healthy lifestyle product platform.  The Company's lead product candidates include Excellagen™ topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.For Terms of Use Privacy Policy, please visit www.cardiumthx.com.Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Announces Receipt of $1.1 Million in Funds from Philips Acquisition of Innercool Therapies
2. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
3. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
4. Cardium Reports on Transdel Transaction
5. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
8. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
9. Cardium to Present at OneMedForum San Francisco 2011 Conference
10. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
11. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology:
(Date:2/11/2016)... Viejo, CA (PRWEB) , ... February 11, 2016 , ... ... Pro X users with customizable backdrops in the Christmas edition of the ProDrop ... of the year. Captivate audiences and invoke the spirit of Christmas using ProDrop's wintry ...
(Date:2/11/2016)... CO. (PRWEB) , ... February 11, 2016 , ... ... people have become more actively engaged in health and wellness best practices in ... importance of riding this trend. February is American Heart Month, which acts as ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... expand dental health services to the developmentally disabled in the Coachella Valley. , ... to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
Breaking Medicine News(10 mins):